Recruiting A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +22 more Locations City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California, United States USC Norris Comprehensive Cancer Center — Los Angeles, California, United States Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States Yale University Cancer Center — New Haven, Connecticut, United States View all 15 locations View more locations Show fewer locations Loading locations... View Trial Details
